CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and
Provides Business Update
Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
July 02, 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 After Only Two Infusions and Two...
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
May 08, 2024 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 25, 2024 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
[Latest] Global Lung Tumor Market Size/Share Worth USD 46.3 Billion by 2033 at a 7.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 15, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, April 15, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lung Tumor Market Size, Trends and Insights By Product (Imaging systems, Biopsy...
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 09, 2024 15:34 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 08, 2024 11:36 ET
|
Revolution Medicines, Inc.
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Forecast to 2032 Across Eight Major Markets (US, France, Germany, Italy, Spain, UK, Japan and Urban China)
April 03, 2024 11:29 ET
|
Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer (NSCLC): Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.Non-small cell lung...
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
March 28, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...